Aurobindo Pharma has announced that Helix Healthcare B.V., a wholly owned subsidiary of the Company, has incorporated a new wholly owned subsidiary in Malaysia by the name of Aurobindo Pharma (Malaysia) SDN. BHD. The object of incorporation of this wholly owned subsidiary is to expand the Pharmaceutical Products business in Malaysia. According to the disclosure on BSE, the Malaysian subsidiary was incorporated on September 17, 2025, with an initial share capital of RM 400,000 (approximately USD 100,000) divided into 400,000 shares of nominal value of RM 1.00 each. No governmental or regulatory approvals were required for this incorporation. Read also:Aurobindo Pharma's subsidiary CuraTeQ Biologics Secures MHRA Approval for Trastuzumab Biosimilar Dazublys in HER2-Positive Cancer Headquartered in Hyderabad, India, Aurobindo Pharma Ltd. is a leading global pharmaceutical company with operations spanning active pharmaceutical ingredients (APIs), generics, and biosimilars. CuraTeQ Biologics is its wholly owned subsidiary focused on biosimilars for oncology and other therapeutic areas, enhancing Aurobindo’s footprint in biologics markets in Europe and beyond.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!